Akebia Ther Stock Performance
| AKBA Stock | USD 1.10 0.03 2.65% |
The firm shows a Beta (market volatility) of 1.34, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Akebia Ther will likely underperform. Akebia Ther has an expected return of -0.13%. Please make sure to confirm Akebia Ther treynor ratio, skewness, and the relationship between the jensen alpha and value at risk , to decide if Akebia Ther performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Akebia Ther has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's fundamental drivers remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
1 | Disposition of 7169 shares by Steven Burke of Akebia Ther at 1.58 subject to Rule 16b-3 | 02/29/2024 |
2 | Acquisition by Nicole Hadas of 200000 shares of Akebia Ther subject to Rule 16b-3 | 03/07/2024 |
3 | FDA Approves For Akebia Therapeutics Vafseo For Kidney Disease Associated Anemia | 03/28/2024 |
4 | Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 - Barchart | 04/30/2024 |
5 | Akebia Therapeutics Set to Announce Quarterly Earnings on Thursday - MarketBeat | 05/03/2024 |
6 | Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | 05/09/2024 |
7 | Akebia Therapeutics Reports Q1 2024 Financial Results A Detailed Overview | 05/10/2024 |
8 | Disposition of 34840 shares by Michel Dahan of Akebia Ther at 1.26 subject to Rule 16b-3 | 05/13/2024 |
9 | Akebia Therapeutics COO Michel Dahan sells 43.9k in stock | 05/14/2024 |
| Begin Period Cash Flow | 90.5 M |
Akebia |
Akebia Ther Relative Risk vs. Return Landscape
If you would invest 135.00 in Akebia Ther on February 23, 2024 and sell it today you would lose (25.00) from holding Akebia Ther or give up 18.52% of portfolio value over 90 days. Akebia Ther is currently does not generate positive expected returns and assumes 6.237% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Akebia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Akebia Ther Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akebia Ther's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akebia Ther, and traders can use it to determine the average amount a Akebia Ther's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0212
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AKBA |
Estimated Market Risk
| 6.24 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Akebia Ther is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akebia Ther by adding Akebia Ther to a well-diversified portfolio.
Akebia Ther Fundamentals Growth
Akebia Stock prices reflect investors' perceptions of the future prospects and financial health of Akebia Ther, and Akebia Ther fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akebia Stock performance.
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.0837 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.44) % | ||||
| Current Valuation | 293.23 M | ||||
| Shares Outstanding | 209.6 M | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 1.57 X | ||||
| Revenue | 194.62 M | ||||
| Gross Profit | 140.04 M | ||||
| EBITDA | (4.23 M) | ||||
| Net Income | (51.92 M) | ||||
| Cash And Equivalents | 143.89 M | ||||
| Cash Per Share | 0.78 X | ||||
| Total Debt | 104.18 M | ||||
| Debt To Equity | 2.15 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (23.38 M) | ||||
| Earnings Per Share | (0.22) X | ||||
| Market Capitalization | 236.84 M | ||||
| Total Asset | 241.7 M | ||||
| Retained Earnings | (1.61 B) | ||||
| Working Capital | 18.28 M | ||||
| Current Asset | 141.02 M | ||||
| Current Liabilities | 11.87 M | ||||
About Akebia Ther Performance
To evaluate Akebia Ther Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Akebia Ther generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Akebia Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Akebia Ther market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Akebia's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 75.62 | 71.84 | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.21) | (0.23) | |
| Return On Equity | 1.70 | 1.78 |
Things to note about Akebia Ther performance evaluation
Checking the ongoing alerts about Akebia Ther for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akebia Ther help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akebia Ther generated a negative expected return over the last 90 days | |
| Akebia Ther has high historical volatility and very poor performance | |
| Akebia Ther may become a speculative penny stock | |
| Akebia Ther has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 194.62 M. Net Loss for the year was (51.92 M) with profit before overhead, payroll, taxes, and interest of 140.04 M. | |
| Akebia Ther currently holds about 143.89 M in cash with (23.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78. | |
| Latest headline from investing.com: Akebia Therapeutics COO Michel Dahan sells 43.9k in stock |
- Analyzing Akebia Ther's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akebia Ther's stock is overvalued or undervalued compared to its peers.
- Examining Akebia Ther's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akebia Ther's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akebia Ther's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akebia Ther's stock. These opinions can provide insight into Akebia Ther's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.Note that the Akebia Ther information on this page should be used as a complementary analysis to other Akebia Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Akebia Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share 0.973 | Quarterly Revenue Growth (0.18) | Return On Assets (0.08) | Return On Equity (5.53) |
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.